| Objectives:To observe the clinical effect of the Anti-fibrosis-1 capsule combined with adefovir dipivoxil in treating the chronic hepatitis B patients, to explore the mechanism of Anti-fibrosis-1 capsule treat Liver fibrosis in chronic hepatitis B and search for an effective method of traditional Chinese and Western medicine treat liver fibrosis, alleviate liver cirrhosis and reduce its incidence, provide reliable clinical evidences for traditional Chinese and Western medicine treat chronic hepatitis B liver fibrosis in case to develop to liver cirrhosis.Methods:Sixty chronic hepatitis B patients were randomly divided into treatment group and control group, each group contains 30 patients. Treatment group is treated by Anti-fibrosis-1 capsule combined with adefovi dipivoxil, specific use:Oral adefovir dipivoxil 10 mg/d,1 time a day. At the same time oral Anti-fibrosis-1 capsule,4 capsules/time,3 times a day; the control group is only treated by adefovir dipivoxil 10 mg/d,1 time a day. The observation time is 12 months, then observe the clinical effect of Anti-fibrosis-1 capsule combined with adefovir dipivoxil and the influence on serum liver fibrosis markers, B-ultrasound examination, liver function and other targets.Results:(1) Treatment effects are significant, the treatment group and control group clinical total effective rate were 86.7% and 53.3%,treatment and control groups was significant difference (p<0.05). (2) Treatment group was better than the control group in improving clinical symptoms, serum liver function ALT,AST,A/G inversion, serum hepatic fibrosis markers such as HA,LN (p<0.05), but there was no significant difference between the two groups in serum ALB,PCâ…¢,TV-C improvement (P>0.05). (3) In the treatment group HBsAg and HBeAg negative conversion rates were 3.33% and 23.33%,there is a certain degree of improvement, but the treatment group compared with the control group, no significant difference(P>0.05); treatment for 6 months, treatment group of HBV-DNA load than the improvement of the control group(P<0.05), but the treatment for 12 months, the control group and treatment group, HBV-DNA load was no significant difference in improvement(P>0.05). (4)After treatment for 12 months, the treatment group and control group, right portal vein diameter, splenic vein diameter, spleen diameter to improve the thickness difference was not statistically significant(P>0.05).Conclusions:(1) Anti-fibrosis-1 capsule can improve the clinical symptoms of the liver fibrosis in chronic hepatitis B patients,has a certain anti-inflammatory liver protection and improve the liver microcirculation and anti-hepatic fibrosis, and to the antiviral activity of adefovir dipivoxil has certain enhancement. (2) Anti-fibrosis-1 capsule combined with adefovi dipivoxil significantly inhibited HBV replication at the same time, can be more effective in improving liver function, relieve symptoms, reduce the degree of liver fibrosis; portal vein diameter,splenic vein diameter and spleen thickness and radius of the anomaly and liver pathology has also shown clear improvement. Compared with the simple use of adefovir dipivoxil, shows unique advantages, is worthy to be popularized.
|
PDF Full Text Request